Merck & Co Inc

-0.42 (-0.53%)
4:00:00 PM EDT: $78.24 -0.03 (-0.04%)
Other Pre-Announcement

Merck KGaA Reports Topline Data For Bintrafusp Alfa

Published: 03/16/2021 07:08 GMT
Merck & Co Inc (MRK) - Merck Kgaa, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa As Second-line Monotherapy Treatment in Biliary Tract Cancer.
In Study of 159 Patients, Bintrafusp Alfa Demonstrated Single-agent Efficacy and Durability With a Manageable Safety Profile After More Than Nine Months of Follow-up, With an Independent Review Committee (irc)-adjudicated Objective Response Rate (orr) of 10.1% (95% Ci: 5.9% to 15.8%) per Recist 1.1.